ClariVest Asset Management LLC Increases Holdings in Emergent Biosolutions Inc (EBS)

ClariVest Asset Management LLC boosted its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 17.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 173,967 shares of the biopharmaceutical company’s stock after acquiring an additional 26,304 shares during the period. ClariVest Asset Management LLC’s holdings in Emergent Biosolutions were worth $10,311,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in EBS. Quantamental Technologies LLC acquired a new position in Emergent Biosolutions during the fourth quarter worth about $29,000. Smithfield Trust Co. raised its position in Emergent Biosolutions by 272.9% during the fourth quarter. Smithfield Trust Co. now owns 2,446 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 1,790 shares during the last quarter. Huntington National Bank raised its position in Emergent Biosolutions by 16.6% during the fourth quarter. Huntington National Bank now owns 2,633 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 374 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Emergent Biosolutions by 37.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,083 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 847 shares during the last quarter. Finally, Financial Gravity Companies Inc. acquired a new position in Emergent Biosolutions during the fourth quarter worth about $204,000. Institutional investors own 83.59% of the company’s stock.

NYSE:EBS opened at $64.43 on Tuesday. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.25 billion, a PE ratio of 33.91, a PEG ratio of 1.02 and a beta of 1.38. Emergent Biosolutions Inc has a 1-year low of $44.49 and a 1-year high of $73.89.

EBS has been the subject of a number of research reports. Goldman Sachs Group upgraded shares of Emergent Biosolutions from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $60.00 to $75.00 in a research report on Friday, November 2nd. Cantor Fitzgerald lifted their target price on shares of Emergent Biosolutions from $68.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd. Argus set a $80.00 target price on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research report on Friday, November 9th. Zacks Investment Research restated a “hold” rating on shares of Emergent Biosolutions in a research report on Tuesday, November 13th. Finally, Cowen restated a “hold” rating and set a $64.00 target price on shares of Emergent Biosolutions in a research report on Tuesday, November 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $68.13.

In other news, Chairman Fuad El-Hibri sold 45,832 shares of the business’s stock in a transaction that occurred on Tuesday, November 27th. The shares were sold at an average price of $69.79, for a total value of $3,198,615.28. Following the completion of the transaction, the chairman now owns 1,428,502 shares of the company’s stock, valued at $99,695,154.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sue Bailey sold 17,717 shares of the business’s stock in a transaction that occurred on Tuesday, November 27th. The shares were sold at an average price of $69.62, for a total transaction of $1,233,457.54. Following the completion of the transaction, the director now directly owns 57,216 shares of the company’s stock, valued at approximately $3,983,377.92. The disclosure for this sale can be found here. In the last three months, insiders sold 98,722 shares of company stock valued at $6,885,390. Company insiders own 13.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ClariVest Asset Management LLC Increases Holdings in Emergent Biosolutions Inc (EBS)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2019/02/12/clarivest-asset-management-llc-increases-holdings-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Story: Momentum Investing

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply